Marchex (MCHX): Targeting $2.00 and a Potential +53% Gain
Key Takeaways
- The central target is $2.00, a round-number resistance level just below the 52-week high of about $2.03, drawn from public technical discussion rather than an analyst consensus.
- At a recent price near $1.31, reaching $2.00 would require a gain of roughly 53%, a very large move.
- Only one current analyst price target exists: Northland Securities' $4.00 Buy target, far above the $2.00 milestone discussed here.
- Supporting factors include an AI-driven product pivot, the pending Archenia acquisition, and rising adjusted EBITDA guidance.
- Key risks are persistent net losses, multi-year revenue contraction, heavy customer concentration, and thin trading liquidity.
How the $2.00 Target Came Into View
Marchex does not have enough credible, current analyst price targets to form a meaningful aggregate. The only verified price target is a $4.00 Buy rating from Northland Securities analyst Michael Latimore, reiterated in July and August 2026. Because a single target cannot support a reliable consensus, this analysis does not treat $4.00 as the central objective. Instead, the $2.00 level comes from identifiable public market discussion: it is a psychological price level sitting just under the stock's 52-week high of approximately $2.03, a prior high that represents a natural technical milestone and resistance zone. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
The shares traded near $1.31 in mid-October 2026, within a 52-week range of roughly $1.15 to $2.03. Moving from $1.31 to $2.00 implies upside of about 53%, which qualifies as a very large required move. The path would require both a fundamental re-rating and a technical breakout: the stock currently sits below its 50-day moving average (about $1.57) and 200-day moving average (about $1.61), with a beta near 1.9 indicating above-market volatility. Trailing twelve-month revenue was roughly $44 million with a net loss near $5.5 million and a price-to-sales (P/S) ratio around 1.5.
What Could Support a Move Toward the Target
Management has positioned Marchex at an "AI inflection point," shifting from standalone analytics toward bundled AI-powered solutions that combine insights, automated actions, and verifiable outcomes. The pending acquisition of Archenia, announced in May 2026, could lift the combined revenue run rate toward roughly $15 million per quarter (about $60 million annualized) with projected growth of 15–20%. Adjusted EBITDA guidance has been raised, with Q3 expected "in the $2 million range or more" and margins trending toward 10% or higher. The balance sheet is also conservative, with low leverage and cash near $8–9 million. From what I see, the AI focus appears central to any re-rating.
What Could Prevent the Target From Being Reached
Marchex has yet to achieve sustained GAAP profitability, and revenue has contracted over multiple years. Roughly 90% of revenue comes from its top 100 customers, creating concentration risk, and the migration of clients to its new Engage platform has pressured revenue run rates. The Archenia deal carries integration and execution risk, and the stock's thin average volume (roughly 30,000–35,000 shares) and high beta can amplify downside. With only one analyst price target, there is little independent confirmation of fair value.
Technical Levels and Market Structure
The 52-week low near $1.15 is the most important downside reference, while $2.00–$2.03 marks the ceiling set by the prior high and a psychological round number. The 50-day (about $1.57) and 200-day (about $1.61) moving averages now sit above the price, acting as overhead supply. A durable reclaim of $1.60–$1.65 would likely be an early signal of improving trend structure before any test of $2.00. I’m watching this closely as the technical setup remains fragile.
Time Horizon and What Investors Should Monitor
The single analyst target reflects a roughly 12-month research horizon, but the $2.00 milestone has no fixed time frame. Investors should watch the next earnings report (estimated around November 12, 2026), the closing and integration of the Archenia acquisition, sequential revenue and adjusted EBITDA progress, any new analyst initiation or target revisions, and whether the stock can hold above its moving averages.
Final Assessment
The $2.00 target is a technical milestone tied to Marchex's 52-week high and a round-number resistance level, not a published analyst consensus. Reaching it would require a roughly 53% advance, a very large move that hinges on successful execution of the AI bundle strategy and the Archenia acquisition, a return to revenue growth, and expansion toward sustainable profitability. Persistent losses, customer concentration, and weak technical structure below the moving averages are the principal obstacles. A single $4.00 analyst target sits well above this level, underscoring the wide uncertainty around the name. Whether $2.00 is attainable depends on fundamentals and sentiment improving in tandem, and investors should monitor earnings, deal integration, and technical levels rather than assume any outcome.
AI Daily Buy/Sell Signals
I have found Tickeron's AI Daily Buy/Sell Signals helpful for monitoring names like this. The tool uses artificial intelligence to continuously track thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a thinly traded, volatile name like MCHX, automated signal monitoring can help stay current on momentum shifts and emerging technical setups without constant manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MCHX's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for MCHX moved out of oversold territory on September 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 30 of the 34 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 63 cases where MCHX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for MCHX just turned positive on September 29, 2026. Looking at past instances where MCHX's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Following a +7.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where MCHX advanced for three days, in 164 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
MCHX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 110 of 153 cases where MCHX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MCHX as a result. In 80 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The 10-day moving average for MCHX crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
The 50-day moving average for MCHX moved below the 200-day moving average on October 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCHX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.016) is normal, around the industry mean (13.387). P/E Ratio (29.140) is within average values for comparable stocks, (43.426). Projected Growth (PEG Ratio) (0.780) is also within normal values, averaging (2.156). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.439) is also within normal values, averaging (1.831).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. MCHX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCHX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of advertising and marketing services
Industry AdvertisingMarketingServices
Advertisement